Neuren Pharmaceuticals (ASX:NEU) received its one-third share of proceeds from Nasdaq-listed partner Acadia Pharmaceuticals' sale of the rare pediatric disease priority review voucher for $150 million in December 2024, according to a Friday filing with the Australian bourse.
The voucher was granted by the US Food and Drug Administration after the approval of Daybue for the treatment of Rett syndrome, the filing said.
Rett syndrome is a genetic disorder characterized by loss of mobility in the hands as development slows down.
The company is entitled to one-third of the proceeds under its license agreement with Acadia, per the filing.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。